熱門資訊> 正文
ImMix Biophma在IMS第20届年会上宣布在NXC-201临床试验中对第9名复发/难治性AL淀粉样变性患者的完全缓解
2023-10-03 21:16
- 100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10-5) observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff
- 100% (4/4) overall response rate and 75% (3/4) complete response rate observed in t(11;14) relapsed/refractory AL Amyloidosis
- Best responder duration of response was 19.2 months with response ongoing; median follow-up of 7.3 months (range: 2.5 – 16.5 months) as of the data cutoff date of September 20, 2023
- ImmixBio plans to submit a BLA for FDA approval in AL Amyloidosis once 40 patients are treated with NXC-201
- The expected primary endpoint for NXC-201 in relapsed/refractory AL Amyloidosis is overall response rate
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
